Connor, Clark & Lunn Investment Management (CC&L)
ECYT

Connor, Clark & Lunn Investment Management (CC&L)’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-63,605
Closed -$1.67M – 680
2014
Q1 		$1.67M Buy
+63,605
New +$922K 0.01% 296

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ECYT Position: Q2 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 63,605 shares — an estimated $1.67M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ECYT in Q1 2014 and held it in 1 quarter. The position peaked at $1.67M in Q1 2014. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 63,605 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $1.67M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Endocyte, Inc. Common Stock position peaked at $1.67M in Q1 2014.
  • 101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2014, filed 14 Aug 2014.